Mitochondrial DNA in the pathogenesis of post-injury coagulopathy
线粒体 DNA 在损伤后凝血病发病机制中的作用
基本信息
- 批准号:10665045
- 负责人:
- 金额:$ 16.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:Advisory CommitteesAgonistAnimal ModelAnimalsAntifibrinolytic AgentsAwardBilateralBiological AssayBiological MarkersBiologyBlood Coagulation DisordersBlood PlateletsCause of DeathCessation of lifeClinicalClinical ResearchCoagulation ProcessCohort StudiesComplexCritical IllnessCytoplasmic GranulesDataDeoxyribonucleasesDevelopmentDiseaseEndothelial CellsExhibitsExtramural ActivitiesFeedbackFibrinolysisFoundationsFunctional disorderFundingGoalsHemorrhageHindlimbHumanImmuneImpairmentIn VitroInflammationInflammatoryInjuryInstitutionInterventionIntravenousKnowledgeLength of StayMediatingMediatorMedical centerMentored Clinical Scientist Development Award (K08)MentorsMentorshipMetforminMississippiMitochondriaMitochondrial DNAModelingMolecularMultiple Organ FailureObservational StudyOperative Surgical ProceduresOrgan failureOrthopedicsOutcomePathogenesisPatientsPatternPhenotypePhysiologyPlasmaPlatelet ActivationPlayPrevalenceRefractoryResearchResearch PersonnelRestResuscitationRodentRodent ModelRoleScientistSurgeonTestingThrombosisTrainingTransfusionTranslatingTraumaTrauma ResearchTrauma patientUniversitiesWorkarmcareerclinical practicedesignexperiencefunctional disabilityhuman studyimprovedimproved outcomeinhibitorinjuredinsightinterestmortalitynew therapeutic targetnovelnovel therapeuticsparticlepharmacologicplatelet functionplatelet phenotypepre-clinicalprospectiveresponse to injurysevere injuryskill acquisitiontargeted treatmenttranslational approachtranslational pipelinetranslational studytrauma induced coagulopathy
项目摘要
PROJECT SUMMARY/ABSTRACT
This application is for a K08 Mentored Clinical Scientist Development Award for Dr. Matthew Kutcher, a trauma
surgeon and surgical intensivist at the University of Mississippi Medical Center. Dr. Kutcher is establishing
himself as an early career investigator in translational trauma research, with a specific interest in the role of
circulating mitochondrial DNA (mtDNA) as a driver of trauma-induced coagulopathy. This proposed K08 award
will accomplish the following goals: (1) provide specific training and mentorship in mitochondrial, platelet, and
fibrinolytic biology; (2) apply these newly-acquired skills and expertise to a translational study of mtDNA as a
driver of trauma-induced coagulopathy, including clinical, mechanistic, and animal model arms; and (3) use these
scientifically and clinically meaningful studies to facilitate independent funding supporting a career as a mature
clinician-scientist. To accomplish these goals, Dr. Kutcher will be mentored by a Scientific Advisory Committee
comprised of content experts and tested mentors. The Committee will be led by Dr. Robert Hester, a key
institutional mentor of Dr. Kutcher’s, and includes leaders in the fields of mitochondrial physiology (Dr. Mark
Gillespie and Dr. Jonathan Hosler) and coagulation biology (Dr. Mitchell Cohen and Dr. Alan Jones). The
Committee is designed to collectively span the translational spectrum from clinical observational studies (Drs.
Cohen and Jones), to mechanistic studies (Drs. Gillespie and Hosler), to preclinical animal models (Dr. Hester)
with a strong foundation of statistical support (Dr. William Hillegass). Strong professional development and
mentorship for a lifelong career as a clinician-scientist will be provided by Drs. Cohen and Jones. This study is
motivated by the prevalence and deleterious effects of platelet dysfunction as a key component of coagulation
abnormalities after injury, for which mechanistic understanding is poor and pharmacologic therapies are lacking.
The central hypothesis of this proposal is that injury-induced release of mtDNA leads to mtDNA-mediated platelet
activation, resulting in functionally impaired circulating platelets and inhibition of systemic fibrinolysis. Although
precedent exists for the importance of mtDNA as a key effector of coagulopathy in clinical observational studies
of trauma and in mechanistic and animal models of other disease states, mtDNA-mediated effects on platelets
have not been studied in trauma. Using a truly translational approach, this proposal will examine a core set of
key platelet and fibrinolytic functional assays, as applied to a prospective human study arm to gain key clinical
insights (AIM 1), an ex vivo study arm in which to probe mechanisms (AIM 2), and an animal study in which to
replicate human findings and evaluate potential interventions (AIM 3). These studies will address a critical
knowledge gap in our understanding of trauma-induced coagulopathy, and identify specific mechanisms and
novel therapeutic targets that will form the basis for a compelling R01 proposal focused on translating these
findings into mitochondrial-targeted therapies to improve our resuscitation of critically injured patients.
项目总结/摘要
此应用程序是K 08指导临床科学家发展奖博士马修库彻,创伤
他是密西西比大学医学中心的外科医生和外科重症监护医师。库彻医生正在建立
他本人是翻译创伤研究的早期职业调查员,对翻译创伤的作用特别感兴趣。
循环线粒体DNA(mtDNA)作为创伤诱导的凝血病的驱动因素。此次K 08奖
将实现以下目标:(1)提供线粒体,血小板,
纤维蛋白溶解生物学;(2)将这些新获得的技能和专业知识应用于mtDNA的翻译研究,
创伤诱导的凝血障碍的驱动因素,包括临床、机械和动物模型组;和(3)使用这些
科学和临床上有意义的研究,以促进独立的资金支持职业生涯作为一个成熟的
临床科学家为了实现这些目标,库彻博士将接受科学咨询委员会的指导。
由内容专家和经过测试的导师组成。该委员会将由罗伯特·赫斯特博士领导,
库彻博士的机构导师,包括线粒体生理学领域的领导者(马克博士
吉莱斯皮和乔纳森·霍斯勒博士)和凝血生物学(米切尔·科恩博士和艾伦·琼斯博士)。的
委员会旨在共同跨越临床观察性研究(Drs.
Cohen和Jones)、机制研究(吉莱斯皮博士和Hosler)、临床前动物模型(Hester博士)
有着坚实的统计学基础(威廉·希莱加斯博士)。强大的专业发展和
科恩博士和琼斯博士将为作为临床科学家的终身职业提供指导。本研究
血小板功能障碍作为凝血的关键成分,
损伤后的异常,其机制的理解是穷人和缺乏药物治疗。
这一建议的中心假设是损伤诱导的mtDNA释放导致mtDNA介导的血小板聚集。
活化,导致功能受损的循环血小板和抑制全身纤维蛋白溶解。虽然
在临床观察性研究中,mtDNA作为凝血障碍的关键效应物的重要性已有先例
在创伤和其他疾病状态的机制和动物模型中,mtDNA介导的对血小板的作用
还没有在创伤中进行过研究。使用真正的翻译方法,本提案将审查一套核心的
关键的血小板和纤溶功能测定,应用于前瞻性人类研究组,以获得关键的临床
洞察力(AIM 1),一个离体研究臂,其中探测机制(AIM 2),和动物研究,其中
复制人类的发现并评估潜在的干预措施(AIM 3)。这些研究将解决一个关键的
我们对创伤引起的凝血功能障碍的理解存在知识差距,并确定具体机制,
新的治疗目标,将形成一个引人注目的R 01提案的基础,重点是翻译这些
研究结果用于脑靶向治疗,以改善我们对严重受伤患者的复苏。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Viscoelastic Hemostatic Assays for Orthopedic Trauma and Elective Procedures.
- DOI:10.3390/jcm11144029
- 发表时间:2022-07-12
- 期刊:
- 影响因子:3.9
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW E KUTCHER其他文献
MATTHEW E KUTCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW E KUTCHER', 18)}}的其他基金
A Proposal to Establish the Mississippi Violence Injury Prevention (VIP) Program
建立密西西比州暴力伤害预防 (VIP) 计划的提案
- 批准号:
10613061 - 财政年份:2022
- 资助金额:
$ 16.2万 - 项目类别:
Mitochondrial DNA in the pathogenesis of post-injury coagulopathy
线粒体 DNA 在损伤后凝血病发病机制中的作用
- 批准号:
10454902 - 财政年份:2020
- 资助金额:
$ 16.2万 - 项目类别:
Mitochondrial DNA in the pathogenesis of post-injury coagulopathy
线粒体 DNA 在损伤后凝血病发病机制中的作用
- 批准号:
10216312 - 财政年份:2020
- 资助金额:
$ 16.2万 - 项目类别:
Mitochondrial DNA in the pathogenesis of post-injury coagulopathy
线粒体 DNA 在损伤后凝血病发病机制中的作用
- 批准号:
10040301 - 财政年份:2020
- 资助金额:
$ 16.2万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)